Graft-versus-myeloma after donor leukocyte infusion: maintenance of marrow remission but extramedullary relapse with plasmacytomas

Bone Marrow Transplantation
A ZomasJ Mehta

Abstract

Adoptive immunotherapy with donor leukocytes has emerged as a promising strategy for the treatment of myeloma recurrence after allogeneic transplantation. 2.9 x 10(8)/kg donor mononuclear cells containing 1.4% CD34+ and 37% CD3+ cells were administered to a 48-year-old patient with non-secretory plasmablastic myeloma relapsing 9 months after a blood stem cell transplant from his HLA-identical sibling. In view of the extensive marrow infiltration and the aggressive behaviour of the disease, the donor cells were preceded by a course of EDAP chemotherapy. There was rapid clinical improvement, and CR was achieved on day 30 post infusion. However, three subcutaneous plasmacytomas showing anaplastic features developed within a few days. These failed to respond to interferon-alpha and continued to grow for 5 weeks in the absence of marrow plasmacytosis or other evidence of systemic disease. Grade 3 acute liver GVHD developed on day 79 which was controlled with immunosuppression. Overt systemic relapse occurred on day 90 as the GVHD came under control. The course of our case suggests highly proliferative malignant cells may escape the graft-versus-tumour effect of immunocompetent allogeneic cells in extramedullary sites subsequently re...Continue Reading

Citations

May 15, 2002·Leukemia Research·David G SavageAttilio Orazi
Mar 14, 2012·Bone Marrow Transplantation·B WirkJ S Moreb
Apr 3, 1999·Current Opinion in Oncology·R L Schlossman, K C Anderson
Nov 5, 1999·Current Opinion in Hematology·F Dazzi, J Goldman
Sep 30, 2005·European Journal of Haematology·Evangelos TerposJane F Apperley
Apr 2, 2002·Best Practice & Research. Clinical Haematology·K S Peggs, S Mackinnon
Jun 9, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Robert Zeiser, Jürgen Finke
Dec 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert ZeiserHartmut Bertz
Jan 10, 2001·Bone Marrow Transplantation·M SalamaR H Collins
Jun 20, 2006·Japanese Journal of Clinical Oncology·Ki-Seong EomChun-Choo Kim
Apr 20, 2002·Cancer Control : Journal of the Moffitt Cancer Center·Leo Luznik, Ephraim J Fuchs
Aug 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H M LokhorstL F Verdonck
Nov 11, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Robbert M SpaapenTuna Mutis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.